Use of sildenafil (Viagra) in patients with cardiovascular disease

Circulation

Volumn 99, Issue 1, 1999, Pages 168-177

  Cheitlin, Melvin D ^a   Hutter Jr , Adolph M ^a   Brindis, Ralph G ^a   Ganz, Peter ^a   Kaul, Sanjay ^a   Russell Jr , Richard O ^a   Zusman, Randall M ^a   Forrester, James S ^a   Douglas, Pamela S ^a   Faxon, David P ^a   Fisher, John D ^a   Gibbons, Raymond J ^a   Halperin, Jonathan L ^a   Hochman, Judith S ^a   Kaul, Sanjiv ^a   Weintraub, William S ^a   Winters Jr , William L ^a   Wolk, Michael J ^a  

^a NONE

Author keywords

ACC AHA Expert Consensus Documents; Angina; Nitric oxide; Sildenafil; Viagra

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ENOXIMONE; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MILRINONE; NITRATE; NITRIC OXIDE; PAPAVERINE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIPERANOMETOZINE; SILDENAFIL; SIMVASTATIN; THEOPHYLLINE; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG EFFECT; DRUG INDUCED DISEASE; ERECTILE DYSFUNCTION; HUMAN; HYPOTENSION; IMPOTENCE; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0033547738     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.1.168     Document Type: Review

References (33)

1. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
2. Shabsigh R, Fishman IJ, Scott FB. Evaluation of erectile impotence. Urology. 1988;32:83-90.
3. Furlow WL. Prevalence of impotence in the United States. Med Aspects Hum Sex. 1985;19:13-16.
4. Tardif GS. Sexual activity after a myocardial infarction. Arch Phys Med Rehabil. 1989;70:763-766.
5. Mitka M. Viagra leads as rivals are moving up. JAMA. 1998;280: 119-120. News.
6. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1997.
7. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction [see comments]. Br J Urol. 1996;78:257-261.
8. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.
9. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Import Res. 1998;10:69-74.
10. Summary of Death Reports in Viagra Received from Marketing (late March) through June 1998. Washington, DC: Food and Drug Administration (Center for Drug Evaluation and Research); 1998.
11. Viagra Deaths of Symptoms Leading to Death Occurring Within Four to Five Hours. New York, NY: Pfizer Inc; 1998. Internal document.
12. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191-236.
13. Naylor AM. Endogenous neurotransmitters mediating penile erection. Br J Urol. 1998;81:424-431.
14. Rajfer J, Aronson WJ, Bush PA, Dory FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326: 90-94.
15. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
16. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 1996;211:1-6.
17. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group [see comments]. N Engl J Med. 1991;325:1468-1475.
18. Terrett NK, Bell AS, Brown D, et al. A potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett. 1996;1819-1824.
19. Nony P, Boissel JP, Lievre M, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis. Eur J Clin Pharmacol. 1994;46:191-196.
20. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997;272:6823-6826.
21. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs. 1987;34:222-262.
22. Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone: mechanisms of action and therapeutic implications. Eur Heart J. 1993;suppl I:34-41.
23. 2+ current: involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 1993;268:26286-26295.
24. Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J. 1993; 14(suppl I):141-148.
25. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990;37:671-681.
26. Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745-1748.
27. Drory Y, Shapira I, Fisman EZ, Pines A. Myocardial ischemia during sexual activity in patients with coronary artery disease [see comments]. Am J Cardiol. 1995;75:835-837.
28. Johnston BL, Fletcher GF. Dynamic electrocardiographic recording during sexual activity in recent post-myocardial infarction and revascularization patients. Am Heart J. 1979;98:736-741.
29. Jackson G. Sexual intercourse and angina pectoris. Int Rehabil Med. 1981;3:35-37.
30. Ueno M. The so-called coition death. Jpn J Leg Med. 1963;17:330-340.
31. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion: Determinants of Myocardial Infarction Onset study investigators [see comments]. JAMA. 1996;275: 1405-1409.
32. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
33. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10. Rockville, Md: Agency for Health Care Policy and Research; 1994. Abstract.